Personalized vaccine helped melanoma patients stay cancer-free longer, drugmakers say
7 Articles
7 Articles
A personalized mRNA vaccine after surgery helps the immune system recognize cancer cells and reduces the risk of melanoma recurrence.
Dr. Elmer Huerta, a medical advisor to RPP, explained that experimental treatment combines immunotherapy with pembrolizumab and a personalized messenger RNA vaccine (MRNA) to combat melanoma. Researchers analyzed the genetic mutations of each patient’s tumor and, through artificial intelligence, identified the most relevant ones to make a specific vaccine for each person.
Two American pharmaceutical companies, Moderna and Merck, announced on August 19 that their jointly developed, personalized mRNA-based cancer vaccine had achieved favorable results in a Phase III clinical trial. Moderna's share price jumped more than 100 percent before the market opened on Friday last week, and the stock eventually closed the trading day with a huge plus. Based on Google Trends data, we looked at how big the announcement made wa…
Two American biotech companies are boasting about creating a personalized mRNA vaccine for melanoma. In theory, such a vaccine could be used to fight many other cancers.
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
